Clinical Trials Arena on MSN
Kamada enrols first subject in Cytogam trial for CMV infection
The controlled multi-centre, randomised, prospective trial is investigating the therapy in kidney transplant recipients.
June is Cytomegalovirus (CMV) Awareness Month, and many parents have never even heard of it. According to the Centers for Disease Control and Prevention, CMV is the leading infectious cause of birth ...
(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company's investigational cytomegalovirus (CMV) vaccine. The study did not meet its ...
Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.
A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback